Bitamdi Soft Capsule 0.5 Micrograms (Alfacalcidol)

Adult dose

Chronic kidney disease and osteoporosis: administer 0.5 to 1 µg of alfacalcidol orally once a day. Hypoparathyroidism and other disorders due to vitamin D metabolism abnormalities: administer 1 to 4 µg of this drug orally once a day.

Child dose

Osteoporosis: administer 0.01 to 0.03 µg per kg body weight orally once a day. Other conditions: administer 0.05 to 0.1 µg per kg body weight orally once a day.

This medication should not be taken by patients with hypercalcemia, hyperphosphatemia, or hypermagnesemia. It should also be avoided if the product of calcium and phosphate in the blood exceeds a certain level, or if there is metabolic alkalosis. Patients with symptoms of vitamin D toxicity or allergies to this drug or its components should not use it. It is advisable not to take magnesium-containing preparations, other vitamin D preparations, calcium-containing preparations, or certain diuretics while using this drug. Nursing women are advised to avoid breastfeeding while taking this medication, and should consult a physician if avoidance is not possible. Women who are pregnant or may become pregnant should consult a healthcare professional before using this medication, and children or the elderly may require dosage adjustments and caution. Patients on specific medications or with a history of kidney stones or sarcoidosis should consult a healthcare professional before using this drug. This medication contains certain dyes, and caution is required for those with a history of allergies. If unusual symptoms occur during use, discontinue the medication immediately and consult a healthcare professional; symptoms may manifest in various systems such as gastrointestinal, nervous, circulatory, renal, liver, skin, eyes, and musculoskeletal systems. Regularly check serum calcium levels and kidney function, and take appropriate actions if abnormalities are found. In case of overdose, stop taking the medication immediately and seek emergency treatment such as hypocalcemia therapy; dosage may be resumed after serum calcium levels return to normal. This medication should be stored out of reach of children, in a cool place protected from direct sunlight and moisture, and in a tightly closed container. It is also important to avoid misuse or abuse and not to transfer it to another container to maintain quality.

Serious side effects

Hives, severe swelling, chest tightness, difficulty breathing, cold sweat, paleness, severe allergic reactions, severe rash with high fever, blisters, peeling skin, pain in mouth/eyes, severe cutaneous adverse reactions, shortness of breath or difficulty breathing, asthma attack, respiratory abnormalities accompanied by cough and fever, yellowing of skin and eyes (jaundice), extreme lethargy, liver abnormalities, sudden and severe headache, lightning-like headache

Mild side effects

• Loss of appetite
• nausea
• vomiting
• diarrhea
• constipation
• stomach pain
• upset stomach
• abdominal distention
• indigestion
• thirst

This medication should be stored in a container that is opaque to light and air, and it is advisable to keep it at room temperature between 1°C and 30°C. Proper storage will help maintain the efficacy of the medication for a longer time.

Appearance

Yellow oval soft capsule containing a colorless or transparent oily substance

Package unit

30 capsules/bottle, 100 capsules/bottle, 100 capsules/box [(10 capsules/PTP X 10)]